Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Systematic Review | Adding rapid diagnostic tests to community‐based programs for treating malaria.

13 Sep, 2022 | 12:57h | UTC

Adding rapid diagnostic tests to community‐based programmes for treating malaria – Cochrane Library

Summary: Does adding rapid diagnostic tests to community-based malaria programmes improve the treatment of people with malaria or fever? – Cochrane Library

 

Two large clinical trials showed Vitamin D supplements do not reduce the risk of Covid-19.

11 Sep, 2022 | 22:56h | UTC

Study 1: Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT) – The BMJ

Study 2: Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial – The BMJ

Editorial: Can vitamin D protect against covid-19? – The BMJ

News Release: No link between vitamin D supplements and reduced risk of covid-19 – BMJ Newsroom

 

Monkeypox: disease epidemiology, host immunity and clinical interventions.

11 Sep, 2022 | 22:54h | UTC

Monkeypox: disease epidemiology, host immunity and clinical interventions – Nature Reviews Immunology

 

Commentary on Twitter

 

Cohort Study | Long-term cardiac pathology in individuals with mild initial COVID-19 illness.

8 Sep, 2022 | 14:44h | UTC

Long-term cardiac pathology in individuals with mild initial COVID-19 illness – Nature Medicine

 

Review | COVID-19 in children.

8 Sep, 2022 | 14:43h | UTC

COVID-19 in Children – Pediatric Clinics of North America

 

Guideline Summary | Management of patients with suspected or confirmed antibiotic allergy.

8 Sep, 2022 | 14:42h | UTC

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

Related:

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 

RCT | Sulopenem (it has both IV and oral formulations) did not meet the criteria for noninferiority compared to Ertapenen for treating complicated urinary tract infections, including pyelonephritis.

8 Sep, 2022 | 14:37h | UTC

Sulopenem For The Treatment of Complicated Urinary Tract Infection Including Pyelonephritis: A Phase 3 Randomized Trial – Clinical Infectious Diseases

 

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.

8 Sep, 2022 | 14:33h | UTC

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial – The Lancet HIV

 

Commentary on Twitter

 

Pediatric infective endocarditis: a literature review.

8 Sep, 2022 | 14:31h | UTC

Pediatric Infective Endocarditis: A Literature Review – Journal of Clinical Medicine

 

Systematic Review | Probiotics for preventing acute upper respiratory tract infections.

6 Sep, 2022 | 14:40h | UTC

Probiotics for preventing acute upper respiratory tract infections – Cochrane Library

 

Commentary on Twitter

 

Study raises concerns about the effectiveness of the monkeypox vaccine.

6 Sep, 2022 | 14:39h | UTC

Study raises concerns about the effectiveness of the monkeypox vaccine – STAT

Original Study (Preprint): Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals – medRxiv

 

Consensus Statement | Cardiac screening prior to return to play after SARS-CoV-2 infection in the child and adolescent athlete. – “Asymptomatic individuals and those with mild symptoms should be cleared by their primary care or team physician, after physical examination and accurate evaluation of medical history”.

6 Sep, 2022 | 14:36h | UTC

Cardiac screening prior to return to play after SARS-CoV-2 infection: focus on the child and adolescent athlete: A Clinical Consensus Statement of the Task Force for Childhood Health of the European Association of Preventive Cardiology

 

Practice update to optimize the performance and interpretation of blood cultures.

6 Sep, 2022 | 14:31h | UTC

Practice update to optimize the performance and interpretation of blood cultures – South African Medical Journal

 

M-A | Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV.

6 Sep, 2022 | 14:27h | UTC

Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis – The Lancet Child & Adolescent Health

 

Commentary on Twitter

 

Systematic Review | Global frequency and clinical features of stroke in patients with tuberculous meningitis.

6 Sep, 2022 | 14:19h | UTC

Global Frequency and Clinical Features of Stroke in Patients With Tuberculous Meningitis: A Systematic Review – JAMA Network Open

 

Perspective | Science, competing values, and trade-offs in public health — the example of Covid-19 and masking.

5 Sep, 2022 | 14:37h | UTC

Science, Competing Values, and Trade-offs in Public Health — The Example of Covid-19 and Masking – New England Journal of Medicine

 

FDA authorizes updated COVID boosters from Moderna and Pfizer.

5 Sep, 2022 | 14:36h | UTC

FDA authorizes updated COVID boosters from Moderna and Pfizer – CIDRAP

FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose – U.S. Food & Drug Administration

 

RCT | Maintaining continuous endotracheal cuff pressure control through an automated electronic device did not reduce the incidence of ventilator-associated respiratory infection.

5 Sep, 2022 | 14:25h | UTC

Effectiveness of Continuous Endotracheal Cuff Pressure Control for the Prevention of Ventilator-Associated Respiratory Infections: An Open-Label Randomized, Controlled Trial – Clinical Infectious Diseases

 

Systematic Review | Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

5 Sep, 2022 | 14:15h | UTC

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis – Cochrane Library

Summary: Treatments to fight fungal infections that cause allergic bronchopulmonary aspergillosis in people with cystic fibrosis – Cochrane Library

 

RCT | Bedaquiline–Pretomanid–Linezolid regimens for drug-resistant tuberculosis.

2 Sep, 2022 | 13:16h | UTC

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Three drug regimen with Linezolid 600 mg tied to better outcomes in drug-resistant TB – Medical Dialogues

 

AHA Scientific Statement | Management of infective endocarditis in people who inject drugs.

1 Sep, 2022 | 12:00h | UTC

Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association – Circulation

News Release: Addiction management is key to treating heart infection in people who inject drugs – American Heart Association

Top Things to Know: Infective Endocarditis in People Who Inject Drugs – American Heart Association

Video: Management of Infective Endocarditis in People who Inject Drugs – American Heart Association

Commentaries:

Infective Endocarditis in People Who Inject Drugs: A Call for Patient-Centered, Multidisciplinary Care – American Heart Association

AHA Addresses Infective Endocarditis in Injection Drug Users – HealthDay

Related: Management of Infective Endocarditis in People Who Inject Drugs – American College of Cardiology (the original article is paywalled but has an informative infographic)

 

Review | Covid-19 vaccines — immunity, variants, boosters.

1 Sep, 2022 | 11:57h | UTC

Covid-19 Vaccines — Immunity, Variants, Boosters – New England Journal of Medicine

 

Risk of BA.5 infection among persons exposed to previous SARS-CoV-2 variants.

1 Sep, 2022 | 11:56h | UTC

Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants – New England Journal of Medicine

 

Commentary on Twitter

 

Cohort Study | Dolutegravir in pregnancy as compared with current HIV regimens.

1 Sep, 2022 | 11:55h | UTC

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States – New England Journal of Medicine (link to abstract – $ for full-text)

Related:

RCT | 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy.

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 

Commentary on Twitter

 

Reports of asymptomatic monkeypox suggest that, at the very least, some infections go unnoticed.

1 Sep, 2022 | 11:54h | UTC

Reports of Asymptomatic Monkeypox Suggest That, at the Very Least, Some Infections Go Unnoticed – JAMA

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.